News

The Government of Canada is taking steps to provide Canadians with effective therapies as part of its response to COVID-19. The Honourable Anita Anand, Minister of Public Services and Procurement and the Honourable Patty Hajdu, Minister of Health, announced...

Regeneron Pharmaceuticals, Inc. announced that the antibody cocktail casirivimab and imdevimab administered together (also known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. FDA. Casirivimab...

CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), and Wacker Chemie AG announced that they had signed a contract for the manufacturing of CureVac’s COVID-19 vaccine candidate CVnCoV. Under...

Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were...

Health Canada granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab (LY-CoV555) as a treatment for adults and pediatric patients 12 years of...

The U.S. FDA issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least...

Elsevier has published the findings of a new report on emerging trends in the pancreatic cancer literature. The report highlights several trending terms including XIST and linc00511. These long non-coding RNAs have the potential to not only be diagnostic/prognostic...